Rising jam band?Formula 5?is gearing up for a big 2018. The Upstate New York upstarts have just announced a 21-show spring tour which spans April and May before culminating with festival appearances at?Domefest, Sterling Stage Folkfest, and Disc Jam Music Festival.?Along the way, Formula 5 will hit the Northeast, Midwest, and Southeast, performing with?Perpetual Groove, McLovins, The Magic Beans, The Southern Belles, Goose,?and Space Carnival.The band has also revealed plans for their second annual ‘Rock The Dock’ Music Festival, set to take place on July 13th, 2018 in Lake George, NY. In addition to Formula 5, Rock The Dock’s musical lineup includes?Soule Monde (Featuring Ray Paczkowski & Russ Lawton of Trey Anastasio Band), Strange Machines, and Let’s Be Leonard,?all of which can be enjoyed from any of the three historic Lake George steamboats that wrap around the stage. Craft and food vendors will also be on hand for Rock The Dock.“Rock The Dock was started as a way to celebrate the Lake George Steamboat Company‘s 200th anniversary by doing something that the company has never done in its history, hold a concert on the pier,” explains event manager Luke Dow. “The concert was a way of giving back to all the loyal patrons as well as showcase the talents of local artists and food trucks. This year’s festival will also be focused on giving back, with 25% of all ticket proceeds benefiting the FUND for Lake George, to help with their efforts to keep the lake clean and pristine for years to come.”You can secure?tickets today on the festival’s website here.For more information?on Formula 5’s spring tour or Rock the Dock, visit?the band’s website.Formula 5 Spring Tour 2018 dates:April 6 – Nectar’s, Burlington, VT*April 7 – Buffalo Iron Works, Buffalo, NY^April 11 – Silk City, Philadelphia, PA*April 12 – DROM, NY, NY*April 13 – Hawks and Reed Performing Arts Center, Greenfield, MA*~April 14 – Pacific Standard Tavern, New Haven, CT*April 19 – The Waterhole, Saranac Lake, NYApril 20 – Jay Peak, Jay, VT$April 26 – Flour City Station, Rochester, NYApril 28 – The Hollow, Albany, NY%May 2 – Woodlands Tavern, Columbus, OHMay 3 – Octave, Covington, KYMay 4 – Lamasco, Evansville, INMay 5 – The Local, Boone, NC@May 7 – Preservation Pub, Knoxville, TNMay 8 – Charleston Pour House, Charleston, SCMay 10 – The Whiskey, Wilmington, NCMay 11 – Tradition Brewing Company, Newport News, VAMay 17 – Domefest, Bedford, PAMay 26 – Sterling Stage Folkfest, Sterling, NYJune 9 – Disc Jam Music Festival, Stephentown, NY* with Goose^ with The Magic Beans~ with The Basement Cats$ with Perpetual Groove and McLovins% with Space Carnival@ with The Southern BellesView Tour Dates
Read Full Story The 2012 Lowell Lecture features Andrew Delbanco, recent winner of the National Humanities Medal. The lecture takes place Wednesday, April 4, in Sever Hall, room 113, at 8 p.mOnce named by Time Magazine as “America’s Best Social Critic,” Delbanco offers a trenchant defense of a college education, and warns that it is becoming a privilege reserved for the relatively rich. In arguing for what a true college education should be, he demonstrates why making it available to as many young people as possible remains central to America’s democratic promise.Delbanco is Levi Professor in the Humanities at Columbia University, and is the author of numerous books including the award-winning Melville: His World and Work (2005). His essays appear regularly in The New York Review of Books, New Republic, New York Times Magazine, and other journals, writing on topics ranging from American literary and religious history to contemporary issues in higher education.A book signing will follow the lecture, with copies of Delbanco’s newly published, College: What it Was, Is, and Should Be, available for purchase.This event is free and open to the public.
Warren E.C. Wacker, former Henry K. Oliver Professor of Hygiene Emeritus, died on Dec. 29, 2012. Wacker held various positions at Harvard over the years. He was an investigator at the Howard Hughes Medical Institute from 1957 to 1968, served as an associate professor of medicine from 1968 to 1971, and was named the Henry K. Oliver Professor of Hygiene in 1971. From then until 1989, he also served as the director of Harvard University Health Services, as well as a House Master to Mather, Kirkland, and Cabot Houses.Read the full obituary.
Capping decades of research, a new study may offer a breakthrough in treating dyskeratosis congenita and other so-called telomere diseases, in which cells age prematurely.Using cells donated by patients with the disease, researchers at the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center identified several small molecules that appear to reverse this cellular aging process. Suneet Agarwal, the study’s senior investigator, hopes at least one of these compounds will advance toward clinical trials. Findings were published Tuesday in the journal Cell Stem Cell.If so, it could be the first treatment for dyskeratosis congenita, or DC, that could reverse all of the disease’s varying effects on the body. The current treatment, bone marrow transplant, is high-risk, and only helps restore the blood system, whereas DC affects multiple organs.Telomeres, telomerase, and healthThe compounds identified in the study restore telomeres, protective caps on the tips of our chromosomes that regulate how our cells age. Telomeres consist of repeating sequences of DNA that get shorter each time a cell divides.The body’s stem cells, which retain their youthful qualities, normally make an enzyme called telomerase that builds telomeres back up again. But when telomeres can’t be maintained, tissues age before their time. A spectrum of diseases can result — not just DC, but also aplastic anemia, liver cirrhosis, and pulmonary fibrosis.The discovery of telomerase 35 years ago, earning a Nobel Prize in 2009, galvanized the scientific world. Subsequent studies suggested the enzyme could be a key to reversing aging, as well as treating cancer, in which malignant cells become “immortal” and divide indefinitely.For years, researchers have tried to find a simple and safe way to manipulate telomerase, preserve telomeres, and create cures for telomere diseases.“Once human telomerase was identified, there were lots of biotech startups, lots of investment,” says Agarwal, who has researched the biology of telomerase for the past decade. “But it didn’t pan out. There are no drugs on the market, and companies have come and gone.”Finding a small molecule for telomere diseasesDC can be caused by mutations in any of multiple genes. Most of these mutations disrupt telomerase formation or function — in particular, by disrupting two molecules called TERT and TERC that join together to form telomerase. TERT is an enzyme made in stem cells, and TERC is a so-called non-coding RNA that acts as a template to create telomeres’ repeating DNA sequences. Both TERT and TERC are affected by a web of other genes that tune telomerase’s action.One of these genes is PARN. In 2015, Agarwal and colleagues showed in Nature Genetics that PARN is important for processing and stabilizing TERC. Mutations in PARN mean less TERC, less telomerase, and prematurely shortened telomeres.The new study, led by Harvard Medical School postdoctoral fellow Neha Nagpal, delved further, focusing on an enzyme that opposes PARN and destabilizes TERC, called PAPD5.“We thought if we targeted PAPD5, we could protect TERC and restore the proper balance of telomerase,” says Nagpal, first author on the paper.Nagpal and her colleagues first conducted large-scale screening studies to identify PAPD5 inhibitors, testing more than 100,000 known chemicals. They got 480 initial “hits,” which they ultimately narrowed to a small handful.They then tested the inhibitors in stem cells made from the Martins’ cells and those of other patients with DC. To the team’s delight, the compounds boosted TERC levels in the cells and restored telomeres to their normal length.But the real challenge was to see if the treatment would be safe and specific, affecting only the stem cells bearing TERT. To test this, the team introduced DC-causing PARN mutations into human blood stem cells, transplanted those cells into mice, then treated the mice with oral PAPD5 inhibitors. The compounds boosted TERC and restored telomere length in the transplanted stem cells, with no adverse effect on the mice or on the ability to form different kinds of blood cells.“This provided the hope that this could become a clinical treatment,” says Nagpal.The road aheadIn the future, Agarwal, Nagpal, and colleagues hope to validate PAPD5 inhibition for other diseases involving faulty maintenance of telomeres — and perhaps even aging itself. They are most excited about two compounds, known as BCH001 and RG7834 that are under further development.“We envision these to be a new class of oral medicines that target stem cells throughout the body,” Agarwal says. “We expect restoring telomeres in stem cells will increase tissue regenerative capacity in the blood, lungs, and other organs affected in DC and other diseases.”For a list of authors and funding sources, visit the website.
Related Shows An entire company is making its Broadway debut in Andrew Upton’s The Present, which officially opens on January 8 at the Ethel Barrymore Theatre. Directed by John Crowley, Upton’s adaptation of Chekhov’s Platonov stars Academy Award winner Cate Blanchett alongside Richard Roxburgh.Set post-Perestroika in the mid-1990s, The Present follows the widow Anna Petrovna (Blanchett) as she celebrates her birthday with a slew of guests; over the course of the party, unresolved relationships and regret quickly rise to the surface.To honor this adaptation of Chekhov’s tale, which also features Anna Bamford, Andrew Buchanan, David Downer, Eamon Farren, Martin Jacobs, Brandon McClelland, Jacqueline McKenzie, Marshall Napier, Susan Prior, Chris Ryan and Toby Schmitz, Broadway.com Resident Artist Justin “Squigs” Robertson gave the cast the Broadway Ink treatment.?Broadway.com wishes The Present’s cast a gift of an opening night and a wonderful time making their Great White Way debut! Catch the show at the Ethel Barrymore Theatre. View Comments About the Artist: With a desire to celebrate the magic of live theater and those who create it, and with a deep reverence for such touchstones as the work of Al Hirschfeld and the wall at Sardi’s, Squigs is happy and grateful to be among those carrying on the traditions where theater and caricature meet. He was born and raised in Oregon, lived in Los Angeles for quite a long time and now calls New York City his home. The Present ? Justin “Squigs” Robertson Show Closed This production ended its run on March 19, 2017
Suzanne Dixon is already asking tough questions and taking the Appalachian Trail Conservancy in new directions.The Appalachian Trail Conservancy (ATC)’s new first female president and CEO, Suzanne Dixon, is intimately familiar with advocating for open spaces. Growing up in Ireland, she spent time as a youngster in its national parks. After moving to the U.S., the first park she visited was Shenandoah. “Protecting this open landscape excited me the most,” she saysAt her previous position at the National Parks Conservation Association (NPCA), she was instrumental in securing the San Antonio Missions National Historical Park as a World Heritage Site (WHS) and in designating other sites and monuments. Afterward, while conversing with a San Antonio taxi driver about local relevance of the designation, he asked, “What does it mean for me?” That’s the question she continually tries to answer with her conservation work—especially now with the ATC.The 2,190-mile A.T. sees over 3 million visitors annually. The Appalachian Trail Conservancy’s founders in 1925 would be astonished at today’s 42,000 members and 6,500 volunteers. To continue this legacy, Dixon hopes to further connect the trail to communities and nearby towns so they can best leverage what’s right in their backyards.“I don’t have many days off lately, but I love to hike, bike, and spend time with my husband and dog. Soccer also has long been a big outlet for me, and I miss it. When I commit to something, I’m all in, so when I don’t have time to train, I won’t show up only to play.Last month, Dixon and the ATC launched its first official economic study of Appalachian Trail communities to look more deeply at the tourism benefits of the A.T. “We have to look beyond the footpath,” says Dixon. A.T hikers traveling to Damascus, for example, could also take advantage of the Virginia Creeper Trail. “These places have a shared identification, because the trail is contiguous,” Dixon says.Another question that Dixon often asks is: “Who’s not at the table?” Dixon suggests that we can learn what’s important to others and expand the tent of people caring about the A.T. Since voices of people of color are often underrepresented in conversations about parks and trails, Dixon says that one solution could be to look to the ATC’s Next Generation Advisory Council, which brings together a group of 18- to 34-year-olds to consult with Congressional leaders about conservation issues and barriers to outdoor recreation and employment. “Congress loves to see their excitement and hear from them,” says Dixon. “The ATC could definitely build on this.”The A.T. is not only about people. With a footprint of 250,000 acres, the A.T. protects one of the largest corridors of green space in the country. Preserving the trail preserves key habitat for species threatened by development and climate change. “The A.T. is ground zero for wildlife corridors,” says Dixon.The ATC also has been publicly opposed to the Mountain Valley Pipeline, which will burrow under the A.T. and run parallel to it for over 90 miles. The ATC will continue to refine its strategies for this and similar issues, since, as Dixon predicts, “The Mountain Valley Pipeline will not be the last pipeline proposed.”This year, the National Trails System Act celebrates its 50th anniversary. Dixon is keenly aware of the challenges presented by today’s divisive political climate, but she remains hopeful. “Public lands are nonpartisan,” she says. “How do we protect and preserve these places together?”In celebration of the National Trail Systems Act, Dixon will be speaking at the Wilderness Skills Institute, located in Pisgah Forest on Wednesday, May 30 at 6 p.m. You can rsvp and find more details here:?https://www.facebook.com/events/195575244591682/
Sign up for our COVID-19 newsletter to stay up-to-date on the latest coronavirus news throughout New York Wait, what? MORE lip syncing? Hey Conforti, this is the best you can come up with for The Buzz? I mean, come on… Beyoncé, Bad Lip Reading, more Beyoncé… Yes, yes it’s all very good, and it makes me want to come to the Long Island Press site every day to see what you have for me, but more lip syncing? Really? And this guy? Is this really going to be worth my time? Is it going to make me smile and maybe LOL and even make a little salty?tear?of delight drip down the side of my face? Is it going to make me want to share it with my friends on Facebook? Host a “Long Island Press ‘Buzz’ item of the Day Viewing Party?” Make me want to send you presents c/o Long Island Press, 575 Underhill Blvd., Syosset, NY 11791 because TOMORROW IS YOUR BIRTHDAY?Yes.(Maybe.)
To access this article REGISTER NOWWould you like print copies, app and digital replica access too? SUBSCRIBE for as little as ￡5 per week. Would you like to read more?Register for free to finish this article.Sign up now for the following benefits:Four FREE articles of your choice per monthBreaking news, comment and analysis from industry experts as it happensChoose from our portfolio of email newsletters
Advertisement Advertisement Metro Sport ReporterSaturday 11 May 2019 10:41 pmShare this article via facebookShare this article via twitterShare this article via messengerShare this with Share this article via emailShare this article via flipboardCopy link116Shares Danny Welbeck has trained before Arsenal’s final Premier League game (Getty Images)Danny Welbeck has returned to full training with Arsenal ahead of their final Premier League game of the season against Burnley on Sunday.The 28-year-old has not featured for the Gunners since November after he required surgery on an ankle injury he suffered in the goalless Europa League draw with Sporting.But the forward has successfully undergone a lengthy rehabilitation programme and trained with his teammates at London Colney on Saturday.Welbeck, who cost ￡16 million from Manchester United in 2014, will leave Arsenal at the end of the season as the club have decided to not renew his contract.ADVERTISEMENTBut he could be given a send-off in front of Arsenal’s fans in their match against Burnley at Turf Moor on Sunday afternoon. Comment Danny Welbeck back in full Arsenal training before Burnley clash Welbeck trained alongside his Arsenal teammates at London Colney (Getty Images)More: FootballRio Ferdinand urges Ole Gunnar Solskjaer to drop Manchester United starChelsea defender Fikayo Tomori reveals why he made U-turn over transfer deadline day moveMikel Arteta rates Thomas Partey’s chances of making his Arsenal debut vs Man CityAdvertisementAdvertisementWelbeck could also potentially play some part in Arsenal’s Europa League final against Chelsea later this month.Despite being expected to miss the rest of the season with his injury, Welbeck was retained in Arsenal’s Europa League squad which was submitted to UEFA at the beginning of February.Unai Emery’s side will face their Premier League rivals in Baku on May 29.More: Manchester United FCRio Ferdinand urges Ole Gunnar Solskjaer to drop Manchester United starNew Manchester United signing Facundo Pellistri responds to Edinson Cavani praiseEx-Man Utd coach blasts Ed Woodward for two key transfer errors
Advertisement Head-to-head in last five meetings 29 Dec 2019 – Arsenal 1-2 Chelsea – Premier League29 May 2019 – Chelsea 4-1 Arsenal – Europa League19 Jan 2019 – Arsenal 2-0 Chelsea – Premier League18 Aug 2018 – Chelsea 3-2 Arsenal – Premier League24 Jan 2018 – Arsenal 2-1 Chelsea – League Cup Chelsea vs Arsenal TV channel, live stream, time, team news, odds and head-to-head Frank Lampard wants another win over Mikel Arteta’s Arsenal (Picture: Getty Images)Chelsea and Arsenal meet in the Premier League for the second time in four weeks on Tuesday night as Mikel Arteta looks for some revenge on Frank Lampard.The Blues handed Arteta his only defeat as Gunners boss so far when they came from behind to win at the Emirates at the end of December.Despite Pierre-Emerick Aubameyang opening the scoring, late goals from Jorginho and Tammy Abraham secured the three points for Lampard’s men in north London.Arsenal have not been beaten since then, but have been held to disappointing draws by Crystal Palace and Sheffield United.ADVERTISEMENTChelsea are coming off a frustrating 1-0 loss at Newcastle on Saturday.AdvertisementAdvertisementWhen is Chelsea vs Arsenal?The match is on Tuesday 21 January with kick-off at 8.15pm at Stamford Bridge.What TV channel is Chelsea vs Arsenal on and is there a live stream?BT Sport 1 will be showing the game live on Tuesday night with coverage starting at 7.30pm.Subscribers can stream the action on BT Sport Player or watch on the BT Sport app.BT Sport 2 will be showing Sheffield United vs Manchester City.More: FootballRio Ferdinand urges Ole Gunnar Solskjaer to drop Manchester United starChelsea defender Fikayo Tomori reveals why he made U-turn over transfer deadline day moveMikel Arteta rates Thomas Partey’s chances of making his Arsenal debut vs Man CityChelsea vs Arsenal odds3/4 Chelsea29/10 Draw15/4 ArsenalOdds courtesy of BetfairChelsea vs Arsenal team newsChelsea remain without Christian Pulisic and Ruben Loftus-Cheek through injury, but Reece James and Marcos Alonso are available after recovering from their respective fitness problems.Mikel Arteta will be without Kieran Tierney, Calum Chambers, Reiss Nelson and Sead Kolasinac through injury, while Pierre-Emerick Aubameyang is suspended.Sokratis missed the last game through illness and is being assessed ahead of the trip across London. Comment Advertisement MORE: Dries Mertens in talks to renew with Napoli amid Arsenal and Chelsea transfer speculationMORE: Timo Werner prefers Liverpool move as Chelsea and Manchester United fight for his signature Metro Sport ReporterTuesday 21 Jan 2020 10:00 amShare this article via facebookShare this article via twitterShare this article via messengerShare this with Share this article via emailShare this article via flipboardCopy link